PMI stands as Myanmar’s inaugural private pharmaceutical manufacturer and is part of the Pacific AA Group. Through strategic investment in this facility, PMI has established the capacity to locally produce high-quality and cost-effective pharmaceutical products for the Myanmar population. This capability is particularly crucial during pandemic scenarios, such as those posed by H1N1, SARS, and COVID-19, when access to imported pharmaceuticals was severely limited.

PMI is a pioneer in the pharmaceutical manufacturing landscape of Myanmar, specializing in the production of high-quality branded and generic medications. This advancement is bolstered by the innovative contributions of a robust international research and development team, which enhances the company’s ability to meet the evolving healthcare needs of the population.

We take pride in our cGMP-compliant facility, which is equipped with the necessary infrastructure and staffed by experienced technical personnel. This enables us to manufacture products that consistently meet reliable quality standards while maintaining affordability for our customers.

We are committed to achieving customer satisfaction by addressing unmet market needs through the accessibility of pharmaceuticals, nutraceuticals, and over-the-counter (OTC) products for both the Myanmar and global markets.